Relmada Therapeutics (NASDAQ:RLMD) Stock Price Expected to Rise, Mizuho Analyst Says

Relmada Therapeutics (NASDAQ:RLMD) had its price objective increased by equities research analysts at Mizuho from $10.00 to $19.00 in a research note issued to investors on Friday,Benzinga reports. The firm currently has an “outperform” rating on the stock. Mizuho’s price objective suggests a potential upside of 213.01% from the company’s previous close.

Several other research analysts have also recently weighed in on RLMD. Weiss Ratings reissued a “sell (e+)” rating on shares of Relmada Therapeutics in a research report on Wednesday, January 28th. Lucid Cap Mkts upgraded shares of Relmada Therapeutics to a “strong-buy” rating in a research report on Monday, March 2nd. Zacks Research raised shares of Relmada Therapeutics to a “hold” rating in a research note on Tuesday, January 27th. Jefferies Financial Group initiated coverage on shares of Relmada Therapeutics in a report on Monday, December 22nd. They issued a “buy” rating and a $9.00 target price on the stock. Finally, Leerink Partners raised shares of Relmada Therapeutics from a “market perform” rating to an “outperform” rating and set a $8.00 price target for the company in a research note on Friday, January 23rd. One equities research analyst has rated the stock with a Strong Buy rating, three have issued a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat, Relmada Therapeutics has a consensus rating of “Moderate Buy” and a consensus target price of $12.00.

Relmada Therapeutics Stock Performance

Shares of Relmada Therapeutics stock opened at $6.07 on Friday. Relmada Therapeutics has a one year low of $0.24 and a one year high of $7.51. The company has a market cap of $445.11 million, a price-to-earnings ratio of -4.19 and a beta of 0.72. The business’s 50 day moving average price is $4.50 and its 200 day moving average price is $3.58.

Relmada Therapeutics (NASDAQ:RLMD) last issued its earnings results on Thursday, March 19th. The company reported ($0.27) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.14) by ($0.13). On average, analysts predict that Relmada Therapeutics will post -2.73 EPS for the current fiscal year.

Institutional Trading of Relmada Therapeutics

A number of hedge funds and other institutional investors have recently modified their holdings of RLMD. Corient Private Wealth LLC raised its holdings in Relmada Therapeutics by 248.2% in the 4th quarter. Corient Private Wealth LLC now owns 719,582 shares of the company’s stock valued at $3,443,000 after buying an additional 512,915 shares during the period. Seven Fleet Capital Management LP purchased a new position in Relmada Therapeutics during the fourth quarter worth about $744,000. Virtu Financial LLC purchased a new position in Relmada Therapeutics during the fourth quarter worth about $85,000. XTX Topco Ltd acquired a new stake in shares of Relmada Therapeutics during the fourth quarter valued at about $199,000. Finally, Ikarian Capital LLC increased its position in shares of Relmada Therapeutics by 66.5% during the fourth quarter. Ikarian Capital LLC now owns 3,068,359 shares of the company’s stock valued at $14,820,000 after acquiring an additional 1,225,299 shares during the last quarter. 45.24% of the stock is owned by institutional investors and hedge funds.

Key Stories Impacting Relmada Therapeutics

Here are the key news stories impacting Relmada Therapeutics this week:

• Positive Sentiment: Mizuho raised its price target sharply to $19 and upgraded RLMD to “Outperform,” implying large upside from current levels — this is a clear buy-side catalyst that can drive buying interest and re-rate sentiment. Read More.
• Positive Sentiment: Company press release highlights audited Q4 and full‑year 2025 results and a corporate update describing “significant progress across its pipeline” (ongoing clinical and strategic milestones). Pipeline advancement tends to support longer-term valuation for clinical-stage biotech. Read More.
• Neutral Sentiment: Earnings call transcripts and highlights from multiple outlets provide management commentary on strategy, program timelines and cash runway; useful for investors parsing catalysts but not an immediate market mover on their own. Review the call transcript for details on enrollment, milestones and guidance. Read More.
• Negative Sentiment: Relmada reported Q4 EPS of ($0.27), missing consensus (~($0.14)) by ~$0.13 — a near-term negative that highlights continued operating losses and may pressure sentiment until clearer revenue or milestone offsets emerge. Read More.

Relmada Therapeutics Company Profile

Relmada Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on the development of novel therapies for pain and other central nervous system (CNS) disorders. The company applies a proprietary stereochemical approach to optimized drug candidates, aiming to improve safety, tolerability and efficacy profiles compared with existing treatments. Relmada’s research efforts center on modulation of NMDA receptors to address unmet needs in depression, neuropathic pain and related indications.

Relmada’s lead product candidate, REL-1017 (d-methadone), is being evaluated as a potential rapid-acting and maintenance treatment for major depressive disorder, with clinical studies underway to assess its utility in both acute and long-term settings.